Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
| Revenue (TTM) | $37.22B |
| Gross Profit (TTM) | $26.59B |
| EBITDA | $16.92B |
| Operating Margin | 33.80% |
| Return on Equity | 101.30% |
| Return on Assets | 8.35% |
| Revenue/Share (TTM) | $69.12 |
| Book Value | $17.03 |
| Price-to-Book | 20.86 |
| Price-to-Sales (TTM) | 5.15 |
| EV/Revenue | 6.37 |
| EV/EBITDA | 14.21 |
| Quarterly Earnings Growth (YoY) | 4.40% |
| Quarterly Revenue Growth (YoY) | 5.80% |
| Shares Outstanding | $539.71M |
| Float | $538.23M |
| % Insiders | 0.22% |
| % Institutions | 85.43% |
Volatility is currently expanding